[Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance]

Frédérique Vegran1, Romain Boidot, Claire Oudin

  • 1Laboratoire de génétique moléculaire, Centre anticancéreux G.F. Leclerc, Inserm U517, 1, rue du Professeur Marion, 21079 Dijon Cedex.

Bulletin Du Cancer
|April 12, 2005
PubMed

Insights

Alternative splice variants of caspase-3 and survivin proteins are altered in human cancers, impacting tumor progression and chemoresistance. Understanding these variants is crucial for developing novel cancer treatments.

Area of Science:

  • Molecular Biology
  • Cancer Biology
  • Genetics

Background:

  • Resistance to apoptosis is linked to chemoresistance in cancer.
  • The inhibitor of apoptosis proteins (IAP) family, including survivin, and caspases like caspase-3, play critical roles in apoptosis regulation.
  • Deregulation and mutations in these proteins are implicated in tumor development.

Purpose of the Study:

  • To review recent data on alternative splice variants of caspase-3 and survivin.
  • To highlight the altered expression of these variants in human cancers.
  • To discuss the association between variant expression and tumor progression/chemoresistance.

Main Methods:

  • Literature review of recent studies on caspase-3 and survivin splice variants.
  • Analysis of data linking variant expression to cancer characteristics.
  • Focus on alternative splicing mechanisms and their functional consequences.

Main Results:

  • Alternative splice variants of caspase-3 (e.g., caspase-3s) and survivin (e.g., survivin-DeltaEx3, survivin-2B, survivin-3B) exhibit divergent apoptotic or anti-apoptotic activities.
  • Expression of these variants is altered in various human cancers.
  • Modified ratios of splice variants correlate with tumor progression and chemoresistance.

Conclusions:

  • Alternative splicing of caspase-3 and survivin generates functionally distinct proteins.
  • Altered expression patterns of these splice variants are significant in human cancers.
  • Targeting alternative splicing pathways may offer novel therapeutic strategies for cancer treatment.

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...